Fuller Insiders Buy the Dip as Analysts Cut Targets

Directors at FUL have been buying stock in the open market at a moment when the Street is pulling back its price targets, creating one of the more interesting divergences in the specialty chemicals space this week.

The insider buying has been consistent and, in one case, meaningful in size. Director R. Jeffrey Bailly purchased 10,000 shares on October 7 at $50.00, a $500,000 open-market commitment made with no 10b5-1 plan in place. A Senior VP added shares on October 16, also outside a pre-arranged plan. Two other directors made smaller purchases in late September, around the $49.50 to $50.00 level. Net insider buying over the past 90 days totals roughly 13,500 shares worth approximately $553,000. All of these are discretionary purchases, which carry more signal than scheduled plan transactions, and all cluster around the same price band where the stock trades today.

That clustering matters because the Street has spent the past month doing the opposite, trimming targets across the board. UBS cut its target to $55 from $69 this week while keeping a Neutral rating. Deutsche Bank, JP Morgan, Citigroup and Baird all reduced targets in late September, with cuts ranging from $5 to $12 per share, although every firm maintained a positive or neutral stance. The consensus mean target is now $66.29, against a current price of $50.57, implying roughly 31% upside on paper. The gap between insider conviction at $50 and analyst targets at $66 is wide. What has narrowed sharply is analyst ambition: JP Morgan had upgraded the stock to Overweight in late June with a $67 target, a call that has not aged well given the stock's trajectory since.

Short positioning is modest rather than aggressive, and the lending market is not signalling stress. Short interest runs at 5.4% of free float, up about 5% on the week but essentially flat over the past month. Availability is extremely loose at 2,703%, meaning there are far more shares available to borrow than are currently borrowed, a condition inconsistent with a crowded short thesis. Cost to borrow is negligible at 0.50%, and has drifted slightly lower over the past month. The ORTEX short score of 41 sits in mid-range territory. Options positioning is likewise neutral, with the put/call ratio at 1.04, barely a fraction of a standard deviation below its 20-day mean of 1.06. None of the lending or options data points to a directional bet of any size.

One data point worth noting from ORTEX Alt Data: H.B. Fuller's Q2 2026 buyback spend came in at $45.8 million, up 182% on the same quarter a year earlier, and the largest Q2 buyback on record for the company going back to 2010. That is a corporate capital allocation signal that runs alongside the insider purchases rather than contradicting them. Wikipedia traffic has also spiked relative to the company's own recent history, with a z-score of 3.2 in late September, suggesting elevated retail attention around the same period the stock was testing these price levels.

Institutionally, BlackRock reported a 15.4% stake as of September 30 with a modest addition. Neuberger Berman added nearly one million shares in the same period, lifting its holding to 4.4% of shares. Dimensional also added. The institutional flow is not dramatic, but it is tilted toward accumulation at these levels, not distribution.

The next earnings event is not until January 13, leaving nearly three months of positioning to play out. The event to watch between now and then is whether the UBS target cut this week, the first move from a major firm since late September, prompts a fresh round of analyst revisions or marks the end of the post-earnings target-trimming cycle.